APA (7th ed.) Citation

Fein, L., Lazaretti, N., Chuken, Y. L., Benfield, J. R. G. R., Mano, M. S., Lobaton, J., . . . Franco, S. (2023). Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate. Clinical Drug Investigation, 43(9), 707. https://doi.org/10.1007/s40261-023-01305-3

Chicago Style (17th ed.) Citation

Fein, Luis, et al. "Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy Is Deemed Appropriate." Clinical Drug Investigation 43, no. 9 (2023): 707. https://doi.org/10.1007/s40261-023-01305-3.

MLA (9th ed.) Citation

Fein, Luis, et al. "Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy Is Deemed Appropriate." Clinical Drug Investigation, vol. 43, no. 9, 2023, p. 707, https://doi.org/10.1007/s40261-023-01305-3.